Abstracts tagged "severity and systemic sclerosis"

Abstract Number: 2939 • 2018 ACR/ARHP Annual Meeting
Clinical Features Associated with Severe Lower Bowel Involvement in Systemic Sclerosis
Eric Dein¹, Laura K. Hummers², Christopher A. Mecoli^3,4 and Zsuzsanna McMahan⁵, ¹Department of Internal Medicine, Johns Hopkins Bayview, Baltimore, MD, ²Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, ³Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵Department of Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Although up to 90% of scleroderma (SSc) patients are affected by gastrointestinal (GI) dysmotility, clinical features of patients with severe lower gastrointestinal involvement are…
Abstract Number: 747 • 2014 ACR/ARHP Annual Meeting
Systemic Sclerosis Patients with Antitopoisomerase Antibodies Showed Significant Association with CCR6 Polymorphisms
Javier Martin¹, Eguzkine Ochoa², Jose Ezequiel Martin¹, Shervin Assassi³, Lorenzo Beretta⁴, Patricia Carreira⁵, Carmen Pilar Simeon⁶, Eugénie Koumakis⁷, Philippe Dieude⁸, Yannick Allanore⁹, Francisco J. García-Hernández¹⁰, Gerard Espinosa¹¹, Ivan Castellvi Barranco¹², Luis Trapiella¹³, Luis Rodriguez Rodriguez¹⁴, Miguel A González-Gay¹⁵, María-Victoria Egurbide¹⁶, Luis Saez¹⁷, José Luis Callejas¹⁸, JA Vargas-Hitos¹⁹, Nicolas Hunzelmann²⁰, Gabriela Riemekasten²¹, Torsten Witte²², Jörg HW Distler²³, Alexander Kreuter²⁴, Claudio Lunardi²⁵, Alessandro Santaniello²⁶, Filemon K. Tan³, Frank C. Arnett³, Paul Shiels²⁷, Ariane L. Herrick²⁸, Jane Worthington²⁹, Madelon C. Vonk³⁰, Bobby P.C. Koeleman³¹, T.R.D.J. Radstake³² and Maureen Mayes³³, ¹Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ²Immunology, Instituto de Parasitología y Biomedicina Lopez Neyra (IPBLN-CSIC), Granada, Spain, ³Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁴Via Francesco Sforza 28, Ospedale Maggiore Policlinico, Milano, Italy, ⁵Hospital Universitario 12 de Octubre, Department of Rheumatology, Madrid, Spain, ⁶Servicio de Medicina Interna, Hospital Valle de Hebron, Barcelona, Spain, ⁷Rheumatology A department, Cochin Hospital, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ⁸Rhumatologie, Hopital Bichat Claude Bernard, Paris, France, ⁹Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France, ¹⁰Internal Medicine, Hospital Virgen del Rocío, Sevilla, Spain, ¹¹Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, ¹²Hosp. De Sta. Creu i S. Pau, Vilafranca del Pened, Spain, ¹³Department of Internal Medicine,, Hospital Universitario Central de Asturias, Asturias, Spain, ¹⁴Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ¹⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ¹⁶Autoimmune Disease Research Unit, Service of Internal Medicine,, Hospital de Cruces, UPV/EHU, Barakaldo, Spain, Barakaldo, Spain, ¹⁷Unidad de Enfermedades Autoinmunes, Servicio de Medicina Interna, Hospital Miguel Servet, Zaragoza, Spain, ¹⁸Internal Medicine, Hospital Clínico San Cecilio, Granada, Spain, ¹⁹Internal Medicine, Hospital Universitario Virgen de las Nieves, Granada, Spain, ²⁰Department of Dermatology, University of Cologne, Cologne, Germany, ²¹Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, ²²Clinic for Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ²³Department of Internal Medicine, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²⁴Department of Dermatology, Venereology, and Allergologie, HELIOS St. Elisabeth Hospital, Oberhausen, Germany, ²⁵Department of Medicine, Università degli Studi di Verona, Verona, Italy, ²⁶Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²⁷University of Glasgow, Glasgow, United Kingdom, ²⁸Musculoskeletal Research Group, School of Translational Medicine, Manchester Academic Health Science Centre, Salford Royal Hospital, University of Manchester., Salford, United Kingdom, ²⁹Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ³⁰Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³¹Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ³²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³³Internal Medicine/Rheumatology, University of TX Health Science Center -Houston, Houston, TX
Background/Purpose: Systemic sclerosis (SSc), also known as scleroderma, is an inflammatory autoimmune disease characterized by fibrosis of the skin and internal organs, vascular damage and…
Abstract Number: 2585 • 2013 ACR/ARHP Annual Meeting
Left Ventricular Dysfunction Reflected By Higher Serum Brain Natriuretic Peptide Accounts For Poorer Prognosis Of Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Sumiaki Tanaka¹, Yoshiyuki Arinuma¹, Tatsuhiko Wada¹, Tatsuo Nagai², Jun Okada³ and Shunsei Hirohata¹, ¹Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ²Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ³Nutritional management, Kitasato Junior Collage of health and Hygienic Sciences, Minami-Uonuma, Japan
Background/Purpose: Recentry, development of potent effective newer drugs for pulmonary arterial hypertension (PAH) have resulted in improving survival of the patients. However, the prognosis of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].